BEIJING, Feb. 27, 2025 /PRNewswire/ — Zhihu Inc. ("Zhihu" or the "Company") (NYSE: ZH; HKEX: 2390), a leading online content community in China, today announced that it will report its unaudited financial results for the quarter and full year ended December 31, 2024 before the U.S. market opens on March 26, 2025.

The Company’s management will host a conference call at 7:00 A.M. U.S. Eastern Time on Wednesday, March 26, 2025 (7:00 P.M. Beijing/Hong Kong Time on Wednesday, March 26, 2025) to discuss the results.

All participants wishing to join the conference call must pre-register online using the link provided below. Once the pre-registration has been completed, each participant will receive a set of dial-in numbers and a unique access PIN which can be used to join the conference call.

Registration Link: https://register-conf.media-server.com/register/BI822b4edc673942e382e2354f17702df3

Additionally, a live and archived webcast of the conference call will be available on the Company’s investor relations website at https://ir.zhihu.com

About Zhihu Inc.

Zhihu Inc. (NYSE: ZH; HKEX: 2390) is a leading online content community in China where people come to find solutions, make decisions, seek inspiration, and have fun. Since the initial launch in 2010, we have grown from a Q&A community into one of the top comprehensive online content communities and the largest Q&A-inspired online content community in China. For more information, please visit https://ir.zhihu.com.

For investor and media inquiries, please contact:

Zhihu Inc.Email: ir@zhihu.com

Christensen AdvisoryRoger HuTel: +86-10-5900-1548Email: zhihu@christensencomms.com

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

SUNRA MIKU-Retrolax: A Blend of Personality, Innovation and Retro

GUANGZHOU, China, Oct. 15, 2024 /PRNewswire/ — Around the global world, we…

Harbour BioMed Announces Business Progress and Update

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 14, 2025 /PRNewswire/ — Harbour BioMed…

Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine

Lundbeck’s new drug application (NDA) for Vyepti® (eptinezumab) accepted by Japan’s Ministry of…